COVID-19 lockdown measures continue to pressure in Q2’21 Moment reported Q2’21 total income of SEK 45m (SEK 20m in government aid), which wa...
Muted off-season quarter with limited impact on full year DistIT delivered relatively soft results w...
USD 9m EBITDA, in line with ABGSCe at USD 9.1m Report unlikely to trigger significant revisions Webc...
Redeye notes that Heliospectra’s Q2 numbers are on par with Q1 and mainly in line with our expectati...
We reiterate our mid-point DCF-based equity value of SEK 55 per share for Nelly Group.
Given we had lowered our estimates ahead of the results, Q2 was a slight disappointment.
Redeye is encouraged by the progress of KL1333 ahead of an expected major capital raise to fund the ...
Q2’21 an eventful quarter with Viscaria re-opening Copperstone reported sales of SEK 0m (ABGSCe 0m) ...
Functional Wood the big explainer OrganoClicks Q2 report came in below our expectations.
Redeye finds only minor deviations in the Q2 report vs our expectations.
Imponerar med både tillväxt och resultat Gullberg & Jansson rapporterar ett starkt andra kvartal prä...
Redeye maintains its view of Nanexa and base case of SEK 9.
Blandat kompott i Q2 Oasmia överraskade i Q2 med Apealea-intäkter och slog därmed våra förväntningar...
Redeye provides its initial take on Westpay’s Q2 report.
Redeye’s estimates were all and all in line with Q2 numbers.
Q3: Healthy organic growth but adj. EBIT lower than last year Atvexa reported Q3 sales of SEK 576m (...
Redeye comments on Azelio's Q2 report, which held no surprises.
Redeye states that Catella's Q2 report came in strong and in line with our expectations.
Enligt estimat Guard Therapeutics rapport för det andra kvartalet var i linje med vår förväntan.
Ökar antalet licenser med 6% q/q Försäljningen för kvartalet kom in på 6,0 mkr (6,0), vilket var und...
Kostnaderna under förväntan Omsättningen uppgick som väntat till 0 mkr under Q2'21.
Redeye continues to view Scibase in a positive light after the Q2 report yesterday.
Redeye believes the Q2 report supports our view that flagship project Emcitate is on track.
Redeye comments on Dignitana's Q2 report. The sales development continues to be positive in uncertai...
Endomines’ Q2 was focused on production start-up and with delays at Friday serious production figure...
Marimekko’s Q2 figures came in above estimates. The company is still only laying out the foundation ...
